Proquin® XR for Uncomplicated UTIs

PLEASE CLICK ON THE LINK BELOW TO FIND INFORMATION ABOUT PROQUIN® XR.

Full prescribing and safety information can be found at www.proquinxr.com.

Commercialization and Partnering

U.S. commercialization of Proquin XR commenced in the fourth quarter of 2005. In July 2007, Depomed and Watson Pharmaceuticals entered into a co-promotion agreement relating to the product. Under the agreement, Depomed has granted Watson a co-exclusive right to promote Proquin XR for the urology and long-term care specialties in the United States and its possessions, including Puerto Rico. In September 2007, the agreement was expanded to grant Watson the right to promote to the Ob/Gyn specialty as well.

With regard to ex-U.S. commercialization, in November 2005 Depomed and Madaus SRL (now Rottapharm) entered into a distribution and supply agreement for Proquin XR. Under the terms of the agreement, Depomed has granted exclusive rights to Rottapharm for the commercialization of Proquin XR in Europe and has agreed to supply Rottapharm with commercial quantities of Proquin XR tablets in bulk form. In exchange, Rottapharm will pay Depomed for Proquin XR tablets at a pre-specified percent of Rottapharm's wholesale ex-factory price, net of packaging costs. Madaus is obligated to obtain regulatory approvals necessary to market Proquin XR within the various European jurisdictions.

If you have any questions regarding our marketing products, please call 1.866.458.6389.